The Design of Nested Adaptive Clinical Trials of Multiple Organ Dysfunction Syndrome Children in a Single Study

被引:3
作者
VanBuren, John M. [1 ]
Hall, Mark [2 ]
Zuppa, Athena F. [3 ]
Mourani, Peter M. [4 ,5 ]
Carcillo, Joseph [6 ]
Dean, J. Michael [1 ]
Watt, Kevin [1 ]
Holubkov, Richard [1 ]
机构
[1] Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA
[2] Nationwide Childrens Hosp, Dept Pediat, Div Crit Care Med, Columbus, OH USA
[3] Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Div Crit Care Med, Philadelphia, PA USA
[4] Univ Arkansas Med Sci, Dept Pediat, Div Crit Care Med, Little Rock, AR USA
[5] Arkansas Childrens Res Inst, Little Rock, AR USA
[6] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med & Pediat, Pittsburgh, PA USA
关键词
adaptive clinical trials; immunomodulation; inflammation; pediatrics; sepsis; TUMOR-NECROSIS-FACTOR; SEVERE SEPSIS; SEPTIC SHOCK; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; RANDOMIZATION; MULTICENTER; MORTALITY; EPIDEMIOLOGY; ANTAGONIST;
D O I
10.1097/PCC.0000000000003332
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
OBJECTIVES: Describe the statistical design of the Personalized Immunomodulation in Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) (PRECISE) study.DESIGN: Children with sepsis-induced MODS undergo real-time immune testing followed by assignment to an immunophenotype-specific study cohort. Interventional cohorts include the granulocyte macrophage-colony stimulating factor (GM-CSF) for the Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS (GRACE)-2 trial, which uses the drug GM-CSF (or placebo) to reverse immunoparalysis; and the Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS) trial, which uses the drug anakinra (or placebo) to reverse systemic inflammation. Both trials have adaptive components and use a statistical framework in which frequent data monitoring assesses futility and efficacy, allowing potentially earlier stopping than traditional approaches. Prespecified simulation-based stopping boundaries are customized to each trial to preserve an overall one-sided type I error rate. The TRIPS trial also uses response-adaptive randomization, updating randomization allocation proportions to favor active arms that appear more efficacious based on accumulating data.SETTING: Twenty-four U.S. academic PICUsPATIENTS: Septic children with specific immunologic derangements during ongoing dysfunction of at least two organs.INTERVENTIONS: The GRACE-2 trial compares GM-CSF and placebo in children with immunoparalysis. The TRIPS trial compares four different doses of anakinra to placebo in children with moderate to severe systemic inflammation.MEASUREMENTS AND MAIN RESULTS: Both trials assess primary efficacy using the sum of the daily pediatric logistic organ dysfunction-2 score over 28 days. Ranked summed scores, with mortality assigned the worst possible value, are compared between arms using the Wilcoxon Rank Sum test (GRACE-2) and a dose-response curve (TRIPS). We present simulation-based operating characteristics under several scenarios to demonstrate the behavior of the adaptive design.CONCLUSIONS: The adaptive design incorporates innovative statistical features that allow for multiple active arms to be compared with placebo based on a child's personal immunophenotype. The design increases power and provides optimal operating characteristics compared with traditional conservative methods.
引用
收藏
页码:e635 / e646
页数:12
相关论文
共 31 条
  • [1] Abraham E, 1998, LANCET, V351, P929
  • [2] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial
    Abraham, E
    Glauser, MP
    Butler, T
    Garbino, J
    Gelmont, D
    Laterre, PF
    Kudsk, K
    Bruining, HA
    Otto, C
    Tobin, E
    Zwingelstein, C
    Lesslauer, W
    Leighton, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19): : 1531 - 1538
  • [3] Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
    Allen, Carl E.
    Yu, Xiaoying
    Kozinetz, Claudia A.
    McClain, Kenneth L.
    [J]. PEDIATRIC BLOOD & CANCER, 2008, 50 (06) : 1227 - 1235
  • [4] The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study Rationale and Design
    Angus, Derek C.
    Berry, Scott
    Lewis, Roger J.
    Al-Beidh, Farah
    Arabi, Yaseen
    van Bentum-Puijk, Wilma
    Bhimani, Zahra
    Bonten, Marc
    Broglio, Kristine
    Brunkhorst, Frank
    Cheng, Allen C.
    Chiche, Jean-Daniel
    De Jong, Menno
    Detry, Michelle
    Goossens, Herman
    Gordon, Anthony
    Green, Cameron
    Higgins, Alisa M.
    Hullegie, Sebastiaan J.
    Kruger, Peter
    Lamontagne, Francois
    Litton, Edward
    Marshall, John
    McGlothlin, Anna
    McGuinness, Shay
    Mouncey, Paul
    Murthy, Srinivas
    Nichol, Alistair
    O'Neill, Genevieve K.
    Parke, Rachael
    Parker, Jane
    Rohde, Gernot
    Rowan, Kathryn
    Turner, Anne
    Young, Paul
    Derde, Lennie
    McArthur, Colin
    Webb, Steven A.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (07) : 879 - 891
  • [5] Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
  • [6] Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection
    Broglio, Kristine R.
    Connor, Jason T.
    Berry, Scott M.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (03) : 685 - 705
  • [7] A Multicenter Network Assessment of Three Inflammation Phenotypes in Pediatric Sepsis-Induced Multiple Organ Failure
    Carcillo, Joseph A.
    Berg, Robert A.
    Wessel, David
    Pollack, Murray
    Meert, Kathleen
    Hall, Mark
    Newth, Christopher
    Lin, John C.
    Doctor, Allan
    Shanley, Tom
    Cornell, Tim
    Harrison, Rick E.
    Zuppa, Athena F.
    Reeder, Ron W.
    Banks, Russell
    Kellum, John A.
    Holubkov, Richard
    Notterman, Daniel A.
    Dean, J. Michael
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2019, 20 (12) : 1137 - 1146
  • [8] A Systemic Inflammation Mortality Risk Assessment Contingency Table for Severe Sepsis
    Carcillo, Joseph A.
    Sward, Katherine
    Halstead, E. Scott
    Telford, Russell
    Jimenez-Bacardi, Adria
    Shakoory, Bita
    Simon, Dennis
    Hall, Mark
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2017, 18 (02) : 143 - 150
  • [9] SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
    Chan, An-Wen
    Tetzlaff, Jennifer M.
    Gotzsche, Peter C.
    Altman, Douglas G.
    Mann, Howard
    Berlin, Jesse A.
    Dickersin, Kay
    Hrobjartsson, Asbjorn
    Schulz, Kenneth F.
    Parulekar, Wendy R.
    Krleza-Jeric, Karmela
    Laupacis, Andreas
    Moher, David
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [10] INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
    Cohen, J
    Carlet, J
    [J]. CRITICAL CARE MEDICINE, 1996, 24 (09) : 1431 - 1440